SUPERNUS PHARMACEUTICALS, INC. (SUPN) Gross profit 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) annual gross profit history from SEC filings — each fiscal year as reported.
$644.4MFY2025 · since FY2016: $203.0M → $644.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $644.4M | +10.4% |
| FY2024 | $583.9M | +11.5% |
| FY2023 | $523.7M | -9.7% |
| FY2022 | $580.0M | — |
| FY2020 | $467.9M | +24.4% |
| FY2019 | $376.1M | -4.4% |
| FY2018 | $393.5M | +37.1% |
| FY2017 | $287.0M | +41.4% |
| FY2016 | $203.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross marginSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →